Hanne Cojoc, QA Manager/Technical Scientist at Valo Therapeutics Finland, holds an M.Sc. (Tech) in Bioengineering from Tampere University, Finland. She has gained broad QA experience ranging from pharmaceutical development to healthcare technology. Hanne has also extensive experience in bio-technical laboratory work in both the clinical and pre-clinical settings.
Drug Discovery Summit (DDS) brings the most innovative event that aims to provide an open and stimulating scientific and cultural exchange that will give all the participants the opportunity to share their experiences, foster collaborations across industry and academia and evaluate emerging technologies across the globe.
The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.
The 3rd Annual European NeoAg Summit is the leading industry-dedicated meeting focused on advancing personalised cancer immunotherapy through neoantigen targeting. Over the last year, there has been a record number of neoantigen-based therapies heading into and through the clinic. In addition, exciting collaborations that bring significant investment into the space means that tumour-specific antigen targeting is set to explode.
This year’s event in Vienna will bring together the “who’s who” from the biotech, pharma and finance segments to allow delegates to meet more key decision makers in three days of partnering meetings than they could in a whole year.